📰 Optune Lua News
Page 9 - Optune Lua News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Optune Lua. Real-time updates on events, politics, business and more.
March 9, 2023
These two defensive stocks should shine in the event of a marketwide correction.
March 8, 2023
These two defensive stocks should shine in the event of a marketwide correction.
January 7, 2023
Successful clinical trial results recently pushed this stock more than 68% higher overnight -- but what about the road ahead?
January 6, 2023
Novocure’s electrical field-producing medical device, in combination with standard drug therapies, improved overall survival in a pivotal study that enrolled patients with advanced non-small cell lung cancer. The medtech company now plans to seek regulatory approvals.
November 26, 2022
The company's technology has a lot of potential. But does its stock?
October 9, 2022
Private Advisor Group LLC trimmed its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Get Rating) by 7.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,403 shares of the medical equipment provider’s stock after selling 362 shares during the period. Private Advisor Group LLC’s […]
August 1, 2022
Arizona State Retirement System grew its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Get Rating) by 2.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 26,009 shares of the medical equipment provider’s stock after purchasing an additional 611 shares during the quarter. Arizona State Retirement System’s holdings in NovoCure were worth $2,155,000 […]
July 18, 2022
Sumitomo Mitsui Trust Holdings Inc. purchased a new position in NovoCure Limited (NASDAQ:NVCR – Get Rating) in the first quarter, HoldingsChannel.com reports. The firm purchased 257,844 shares of the medical equipment provider’s stock, valued at approximately $21,362,000. A number of other hedge funds and other institutional investors have also bought and sold shares of the […]
May 29, 2022
Brokerages expect that NovoCure Limited (NASDAQ:NVCR – Get Rating) will post earnings per share (EPS) of ($0.14) for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for NovoCure’s earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.06). NovoCure also reported earnings per share of ($0.14) in the […]
May 29, 2022
Equities analysts predict that NovoCure Limited (NASDAQ:NVCR – Get Rating) will announce ($0.14) earnings per share for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for NovoCure’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.25). NovoCure also reported earnings of ($0.14) […]